2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now

Bristol Myers Squibb (BMY) yields ~3.76% (quarterly dividend $0.63, +1.6% y/y) with a free-cash-flow payout ratio ~45%, while Pfizer (PFE) yields ~6.04% (quarterly dividend $0.43, +2.3% last year) but has a higher FCF payout ratio ~89%, implying less dividend margin of safety. Share performance is strong this year (+23% BMY, +14% PFE), but both face revenue replacement risks from legacy drug patent losses and COVID-19 declines. BMY’s Q2 legacy revenue fell 4% y/y to $5.4B while its growth portfolio rose 15% to $7.6B; Pfizer’s Comirnaty and Paxlovid sales dropped 34% and 95% y/y, but launched/acquired products grew 18% operationally.

Analysis

The market is treating both names as “cheap income,” but the cash-flow quality gap matters more than the headline yield. BMY has enough internal financing capacity to keep buying time for its replacement portfolio, which supports a higher multiple floor; PFE’s higher yield looks attractive until you map it against limited FCF headroom and a slower operating inflection, which raises the odds of a dividend-growth stall and keeps the stock in bond-proxy territory.

Second-order, this is less about a single quarter and more about who can sustain capital allocation flexibility through 1-3 years of LOE replacement. If BMY’s growth assets continue compounding, it can redirect cash toward pipeline/debt without forcing a payout debate; if PFE’s launch mix fails to scale fast enough, management will be boxed into choosing between payout discipline and investment intensity, which is a recipe for multiple compression even without an outright cut.

The contrarian view is that consensus may be underestimating how durable income investors can be: a high yield can support the stock for longer than fundamentals suggest, especially if rates fall. So the cleaner edge is not an outright short on PFE, but a relative-value expression that isolates cash-flow quality and dividend safety, while watching for any guidance that shows FCF conversion inflecting above current expectations. Key falsifier: if PFE’s next 2 quarters show materially better free cash flow and operating margin expansion, the dividend-risk discount should narrow quickly.

Key Decisions for Investors

• Go long BMY / short PFE as a 3-6 month relative-value pair; thesis is that BMY’s lower payout ratio and better replacement runway deserve multiple support while PFE remains capped by dividend-safety skepticism.
• If using single names, prefer BMY over PFE for income exposure; accumulate on market weakness ahead of the next earnings cycle, when cash-flow guidance is most likely to re-rate the spread.
• For higher-conviction but limited-risk expression, buy BMY call spreads 3-6 months out and fund part of the premium with out-of-the-money PFE put spreads; structure benefits if the market rewards balance-sheet flexibility over headline yield.
• Watch PFE free cash flow and dividend payout ratio in the next two quarters; if payout remains near current levels and launch revenue fails to accelerate, reduce exposure or press the short leg.
• Use JNJ as a defensive peer benchmark rather than a trade here; if JNJ multiple holds and BMY/PFE do not close the valuation gap, the market is signaling that balance-sheet quality is the dominant factor.